PROGRAMMED death-ligand 1PROGRESSION-free survivalOVERALL survivalSURVIVAL rateSQUAMOUS cell carcinomaBackground: Recently, a sum of trials of programmed cell death-1 (PD-1) inhibitors combined with chemotherapy have shown excellent efficacy compared to chemotherapy alone in patients...
Yong Li, et al. Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study. Presented at...
Yong Li, et al. Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study. Presented at: the European Society for Medical Oncology (ESMO) World Congress on Oesoph...
参考文献:Chen Z, Wang K, Zhao L and Gong L (2023) BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report. Front. Oncol. 13:1190100. doi: 10.3389/fonc.2023.1190100
[4]Nishino M, Ramaiya NH, Chambers ES, et al. Immune-related response assessmentduring PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 2016;4:84. [5]Xie G, Gu D, Zhang L, et al. A rapid and systemic complete response to stereotactic body ra...
免疫组织化学(immunohistochemistry,IHC,简称免疫组化)检测是评估肿瘤组织PD-L1表达状态的一种有效且最常用方法,广泛应用于包括非小细胞肺癌(non-small cell lung cancer, NSCLC)等在内的多种恶性肿瘤中,以识别或辅助预测可能从免疫治疗中获...
近年来,以程序性死亡受体1(programmed death-1, PD-1)/PD配体1(PD ligand 1, PD-L1)免疫检查点抑制剂为主的免疫治疗在晚期肺癌中取得了突破性的进展,改变了该领域的治疗格局,为患者带来了更多生存获益。虽然对于免疫治疗适宜人群筛选和疗效预测的生物标志物越来越多,但PD-L1仍是目前应用最为广泛的指标。免疫组...
pd-1信号抑制剂的并用疗法 1.本技术是申请日为2016年12月5日的中国专利申请201680081286.8“pd-1信号抑制剂的并用疗法”的分案申请。 技术领域 2.本发明涉及pd-1(programmedcelldeath-1,程序性细胞死亡-1)信号抑制剂的并用疗法。 背景技术: 3.近年来的临床试验的结果表明,抗pd-1抗体治疗是在各种癌症中较以...
Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung 来自 学术范 喜欢 0 阅读量: 54 摘要: Background:A single-agent of anti programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) therapy has ...
RasmussenJH, LelkaitisG, HåkanssonK, et al.Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma[J]. Br J Cancer, 2019, 120(10):1003-1006. DOI: 10.1038/s41416-019-0449-y. GradeckiSE, GrangeJS...